Table 1.

PDR patients. Data are n unless indicated otherwise and are expressed as mean ± SD.

Patients/Eyes	39/42
Clinical features
Gender (male/female)	28/11
Age (years)	65 ± 10
Type 1/type 2 diabetes	4/35
Duration of diabetes (years)	21 ± 6
Oral hypoglycemic drug treatment	10/39
Insulin treatment	10/39
Oral hypoglycemic drug + insulin treatment	19/39
Glycaemia (mg/dL)	161 ± 56
HbA1c (%)	7.9 ± 1.1
Neuropathy	6/39
Nephropathy	13/39
Cardiopathy	15/39
Hypertension	37/39
Dyslipidemia	23/39
Triglycerides (mg/dL)	120 ± 54
Cholesterol (mg/dL)	153 ± 44
Creatinine (mg/dL)	1.4 ± 0.7
Hemoglobin (g/dL)	13.1 ± 1.6
Ophthalmic features
PDR	42/42
PDR with vitreous hemorrhage	19/42
PDR with macular edema	19/42
PDR with ERM	31/38
Ocular therapies
Intravitreal injection of anti-VEGF blocker	29/42
Panretinal laser photocoagulation	32/42

Abbreviations: ERM: epiretinal membranes; PDR: proliferative diabetic retinopathy; VEGF: vascular endothelial growth factor.